# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Post-transplant lymphoproliferative disease

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 16 results.
Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder
Status: Not yet recruiting
Last Changed: Jun 30, 2020
First Received: Apr 08, 2020
Disease(s): Post-transplant Lymphoproliferative Disorder
Intervention(s): Rituximab, Acalabrutinib, CT scans
Locations: Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab
Status: Recruiting
Last Changed: Jul 22, 2020
First Received: Jan 05, 2018
Disease(s): Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD), Stem Cell Transplant Complications, Lymphoproliferative Disorders
Intervention(s): tabelecleucel
Locations: University of California San Diego Moores Cancer Center (Adults Only), La Jolla, California, United States
Children's Hospital of Colorado (Pediatrics Only), Aurora, Colorado, United States
Lombardi Comprehansive Cancer Center (Adults and Pediatrics), Washington, District of Columbia, United States
University of Miami/Jackson Memorial Hospital (Adults only), Miami, Florida, United States
Winship Cancer Institute of Emory University (Adults only), Atlanta, Georgia, United States
... and 23 other locations.
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
Status: Recruiting
Last Changed: Jul 28, 2020
First Received: Jan 09, 2018
Disease(s): Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Intervention(s): tabelecleucel
Locations: City of Hope (Adults and Pediatrics), Duarte, California, United States
University of California San Diego Moores Cancer Center (Adults only), La Jolla, California, United States
Loma Linda University Cancer Center (Adults only), Loma Linda, California, United States
UCLA Medical Center (Adults and Pediatrics), Los Angeles, California, United States
University of California Davis Comprehensive Cancer Center (Adults only), Sacramento, California, United States
... and 39 other locations.
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Recruiting
Last Changed: Jun 11, 2020
First Received: Sep 15, 2016
Disease(s): EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
Intervention(s): Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes, Rituximab
Locations: Children's Hospital of Alabama, Birmingham, Alabama, United States
Phoenix Childrens Hospital, Phoenix, Arizona, United States
Loma Linda University Medical Center, Loma Linda, California, United States
Children's Hospital Los Angeles, Los Angeles, California, United States
Mattel Children's Hospital UCLA, Los Angeles, California, United States
... and 34 other locations.
Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant
Status: Recruiting
Last Changed: Mar 31, 2020
First Received: Apr 27, 2017
Disease(s): Post-transplant Lymphoproliferative Disease, Transplant-Related Hematologic Malignancy
Intervention(s): Autologous EBV-CTL transduced with vector SFG-CNA12, Autologous EBV-CTL transduced with control vector SFG-CNA8, Leucapheresis
Locations: Great Ormond Street Hospital, London, United Kingdom
King's College Hospital, London, United Kingdom
A Study of the Safety and Efficacy of EBV Specific T-cell Lines
Status: Recruiting
Last Changed: Aug 15, 2019
First Received: Oct 20, 2015
Disease(s): Epstein-Barr Virus Infections, Post-Transplant Lymphoproliferative Disorder, Lymphoma
Intervention(s): Group A, Group B
Locations: Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Status: Not yet recruiting
Last Changed: Aug 04, 2020
First Received: Feb 28, 2020
Disease(s): Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma, Post-transplant Lymphoproliferative Disorder
Intervention(s): CD30.CAR-EBVST cells
Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Apr 27, 2016
First Received: Apr 27, 2016
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): bendamustine, rituximab
Locations: Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of
EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients
Status: Recruiting
Last Changed: Dec 10, 2019
First Received: Dec 06, 2019
Disease(s): EBV Infection, EBV Viremia, Epstein-Barr Virus Associated Lymphoproliferative Disorder, Post-transplant Lymphoproliferative Disorder
Intervention(s): EBV DNA in whole blood and plasma
Locations: Aarhus University Hospital, Aarhus, Central Region Of Denmark, Denmark
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
Status: Available
Last Changed: Jul 17, 2020
First Received: Jul 04, 2016
Disease(s): Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Epstein-Barr Viremia, Lymphoma, AIDS-related, Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID), Leiomyosarcoma (LMS), Nasopharyngeal Carcinoma (NPC), Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID), Solid Organ Transplant Complications, Stem Cell Transplant Complications
Intervention(s): tabelecleucel